HRP20212002T1 - Synthesis of boronic ester and acid compounds - Google Patents

Synthesis of boronic ester and acid compounds Download PDF

Info

Publication number
HRP20212002T1
HRP20212002T1 HRP20212002TT HRP20212002T HRP20212002T1 HR P20212002 T1 HRP20212002 T1 HR P20212002T1 HR P20212002T T HRP20212002T T HR P20212002TT HR P20212002 T HRP20212002 T HR P20212002T HR P20212002 T1 HRP20212002 T1 HR P20212002T1
Authority
HR
Croatia
Prior art keywords
compound
formula
acid
xiv
boric
Prior art date
Application number
HRP20212002TT
Other languages
Croatian (hr)
Inventor
Fraser I. Pickersgill
John Bishop
Young Lo
Fang-Ting Chui
Vithalanand R. Kulkarni
Original Assignee
Millennium Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34968044&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20212002(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Millennium Pharmaceuticals, Inc. filed Critical Millennium Pharmaceuticals, Inc.
Publication of HRP20212002T1 publication Critical patent/HRP20212002T1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic System
    • C07F5/02—Boron compounds
    • C07F5/04—Esters of boric acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic System
    • C07F5/02—Boron compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic System
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Claims (7)

1. Postupak za formiranje anhidrida borove kiseline spoja formule (XIV): [image] koji sadrži korake: (A) spajanja adicione soli trifluoroctene kiseline spoja formule (XVIII): [image] sa spojem formule (XIXa): [image] pri čemu, grupa -C(O)X je aktivirani ester generiran in situ dovođenjem u kontakt N-(2-pirazinkarbonil)-L-fenilalanina sa dicikloheksilkarbodiimidom i N-hidroksisukcinimidom, pri čemu, grupa C(O)-X je O-(N-hidroksisukcinimid)ester, da se formira spoj formule (XXIII): [image] i (B) uklanjanja zaštite sa ostatka borove kiseline da bi se formirao anhidrid borove kiseline spoja formule (XIV); pri čemu korak spajanja (A) sadrži: (i) osiguravanje otopine (1R)-(S)-pinandiol 1-amonij trifluoroacetat-3-metilbutan-1-boronata i N-hidroksisukcinimida, nakon čega slijedi dodavanje dicikloheksilkarbodiimida da bi se formirala suspenzija; (ii) osiguravanje otopine N-(2-pirazinkarbonil)-L-fenilalanina i dodavanje N-metilmorfolina u njega; (iii) dodavanje otopine dobivene iz koraka (ii) u suspenziju dobivenu iz koraka (i) i izborno podešavanje dobivene suspenzije do pH 7 dodavanjem N-metilmorfolina; i pri čemu korak spajanja (A)(i) sadrži osiguravanje otopine (1R)-(S)-pinandiol 1-amonij trifluoroacetat-3-metilbutan-1-boronata i N-hidroksisukcinimida u DMF, nakon čega slijedi dodavanje dicikloheksilkarbodiimida da bi se formirala suspenzija; i/ili korak spajanja (A)(ii) obuhvaća osiguravanje otopine N-(2-pirazinkarbonil)-L-fenilalanina u DMF i dodavanje N-metilmorfolina u to.1. Process for the formation of boric anhydride of the compound of formula (XIV): [image] which contains the steps: (A) joining the trifluoroacetic acid addition salt of the compound of formula (XVIII): [image] with the compound of formula (XIXa): [image] wherein the -C(O)X group is an activated ester generated in situ by contacting N-(2-pyrazinecarbonyl)-L-phenylalanine with dicyclohexylcarbodiimide and N-hydroxysuccinimide, wherein the C(O)-X group is O- (N-hydroxysuccinimide) ester, to form a compound of formula (XXIII): [image] and (B) deprotection of the boric acid residue to form the boric anhydride compound of formula (XIV); where the joining step (A) contains: (i) providing a solution of (1R)-(S)-pinanediol 1-ammonium trifluoroacetate-3-methylbutane-1-boronate and N-hydroxysuccinimide, followed by addition of dicyclohexylcarbodiimide to form a suspension; (ii) providing a solution of N-(2-pyrazinecarbonyl)-L-phenylalanine and adding N-methylmorpholine thereto; (iii) adding the solution obtained from step (ii) to the suspension obtained from step (i) and optionally adjusting the resulting suspension to pH 7 by adding N-methylmorpholine; and wherein coupling step (A)(i) comprises providing a solution of (1R)-(S)-pinanediol 1-ammonium trifluoroacetate-3-methylbutane-1-boronate and N-hydroxysuccinimide in DMF, followed by addition of dicyclohexylcarbodiimide to form suspension; and/or coupling step (A)(ii) comprises providing a solution of N-(2-pyrazinecarbonyl)-L-phenylalanine in DMF and adding N-methylmorpholine thereto. 2. Postupak prema bilo kojem prethodnom zahtjevu, naznačen time što se korak uklanjanja zaštite sa borove kiseline (B) izvodi u prisustvu akceptora organske borove kiseline (izborno 2-metilpropanborove kiseline), nižeg alkanola (izborno metanola), C5-8 ugljikovodičnog otapala (izborno heksana) i vodene mineralne kiseline (izborno HCl).2. Process according to any preceding claim, characterized in that the deprotection step from boric acid (B) is performed in the presence of an organic boric acid acceptor (optionally 2-methylpropaneboric acid), a lower alkanol (optionally methanol), a C5-8 hydrocarbon solvent ( optionally hexane) and aqueous mineral acid (optionally HCl). 3. Postupak prema zahtjevu 2, naznačen time što se korak uklanjanja zaštite sa borove kiseline (B) izvodi u prisustvu 2-metilpropanborove kiseline, metanola, heksana i HCl.3. The method according to claim 2, characterized in that the step of deprotection from boric acid (B) is performed in the presence of 2-methylpropaneboric acid, methanol, hexane and HCl. 4. Postupak prema bilo kojem od prethodnih zahtjeva, naznačen time što korak uklanjanja zaštite sa borove kiseline (B) sadrži korake: (i) osiguravanje dvofazne mješavine koja sadrži spoj formule (XXIII), akceptor organske borove kiseline, niži alkanol, C5-8 ugljikovodično otapalo i vodenu mineralnu kiselinu; (ii) miješanja dvofazne mješavine da bi se dobilo spoj formule (XIV) na temperaturi od 15 do 25°C; (iii) odvajanja slojeva otapala; i (iv) ekstrakciju anhidrida borove kiseline spoja formule (XIV) u organsko otapalo.4. The method according to any of the preceding claims, characterized in that the step of removing protection from boric acid (B) contains the steps: (i) providing a biphasic mixture comprising a compound of formula (XXIII), an organoboric acid acceptor, a lower alkanol, a C5-8 hydrocarbon solvent and aqueous mineral acid; (ii) stirring the biphasic mixture to obtain the compound of formula (XIV) at a temperature of 15 to 25°C; (iii) separation of solvent layers; and (iv) extraction of the boric anhydride of the compound of formula (XIV) into an organic solvent. 5. Postupak prema zahtjevu 4, naznačen time što korak (B)(iii) sadrži korake: (1) odvajanja slojeva otapala; (2) podešavanja vodenog sloja do baznog pH; (3) ispiranja vodenog sloja organskim otapalom; i (4) podešavanja vodenog sloja do pH manjeg od 8.5. The method according to claim 4, characterized in that step (B)(iii) contains the steps: (1) separation of solvent layers; (2) adjustments of the aqueous layer to base pH; (3) washing the aqueous layer with an organic solvent; and (4) adjustments of the aqueous layer to a pH of less than 8. 6. Postupak prema zahtjevu 5, naznačen time što se u koraku (B)(iii)(4), vodeni sloj podešava do pH manjeg od 6.6. The method according to claim 5, characterized in that in step (B)(iii)(4), the aqueous layer is adjusted to a pH of less than 6. 7. Postupak prema zahtjevu 4, naznačen time što se u koraku (B)(iv), anhidrid borove kiseline spoja formule (XIV) ekstrahira u etil acetat, i anhidrid borove kiseline spoja formule (XIV) se istaloži dodavanjem terc-butilmetil etera.7. The process according to claim 4, characterized in that in step (B)(iv), the boric anhydride of the compound of formula (XIV) is extracted into ethyl acetate, and the boric anhydride of the compound of formula (XIV) is precipitated by adding tert-butylmethyl ether.
HRP20212002TT 2004-03-30 2005-03-24 Synthesis of boronic ester and acid compounds HRP20212002T1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US55753504P 2004-03-30 2004-03-30
EP18172486.5A EP3385267B1 (en) 2004-03-30 2005-03-24 Synthesis of boronic ester and acid compounds

Publications (1)

Publication Number Publication Date
HRP20212002T1 true HRP20212002T1 (en) 2022-04-01

Family

ID=34968044

Family Applications (4)

Application Number Title Priority Date Filing Date
HRP20240307TT HRP20240307T3 (en) 2004-03-30 2005-03-24 Synthesis of boronic ester and acid compounds
HRP20212002TT HRP20212002T1 (en) 2004-03-30 2005-03-24 Synthesis of boronic ester and acid compounds
HR20110846T HRP20110846T1 (en) 2004-03-30 2011-11-14 Synthesis of boronic ester and acid compounds
HRP20140339TT HRP20140339T1 (en) 2004-03-30 2014-04-08 Synthesis of bortezomib

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HRP20240307TT HRP20240307T3 (en) 2004-03-30 2005-03-24 Synthesis of boronic ester and acid compounds

Family Applications After (2)

Application Number Title Priority Date Filing Date
HR20110846T HRP20110846T1 (en) 2004-03-30 2011-11-14 Synthesis of boronic ester and acid compounds
HRP20140339TT HRP20140339T1 (en) 2004-03-30 2014-04-08 Synthesis of bortezomib

Country Status (41)

Country Link
US (14) US7714159B2 (en)
EP (5) EP2377869B1 (en)
JP (4) JP4558039B2 (en)
KR (1) KR100939598B1 (en)
CN (5) CN107474062A (en)
AR (3) AR049374A1 (en)
AT (1) ATE521612T1 (en)
AU (1) AU2005230930B2 (en)
BR (1) BRPI0509587A (en)
CA (4) CA2859119A1 (en)
CL (2) CL2010000350A1 (en)
CR (1) CR8653A (en)
CY (3) CY1112053T1 (en)
DK (4) DK1756121T3 (en)
DO (1) DOP2011000293A (en)
EA (1) EA012927B1 (en)
EC (1) ECSP066960A (en)
ES (3) ES2457593T3 (en)
FI (1) FI4008721T3 (en)
HK (4) HK1100004A1 (en)
HR (4) HRP20240307T3 (en)
HU (1) HUE056859T2 (en)
IL (3) IL178250A (en)
LT (2) LT3385267T (en)
ME (1) ME01975B (en)
MX (1) MX367324B (en)
MY (1) MY145427A (en)
NL (3) NL1028639C2 (en)
NO (4) NO338905B1 (en)
NZ (3) NZ550522A (en)
PE (3) PE20060162A1 (en)
PL (3) PL1756121T3 (en)
PT (4) PT1756121E (en)
RS (4) RS65253B1 (en)
SG (5) SG10201800972PA (en)
SI (3) SI2377869T1 (en)
TW (1) TWI386212B (en)
UA (1) UA90108C2 (en)
UY (3) UY28830A1 (en)
WO (1) WO2005097809A2 (en)
ZA (1) ZA200608689B (en)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6083903A (en) 1994-10-28 2000-07-04 Leukosite, Inc. Boronic ester and acid compounds, synthesis and uses
FI4008721T3 (en) 2004-03-30 2024-03-19 Millennium Pharm Inc Synthesis of boronic ester and acid compounds
WO2008075376A1 (en) * 2006-12-18 2008-06-26 Natco Pharma Limited Polymorphic forms of bortezomib and process for their preparation
WO2009004350A1 (en) * 2007-07-03 2009-01-08 Pliva Hrvatska D.O.O. Methods for preparing bortezomib and intermediates used in its manufacture
US7442830B1 (en) 2007-08-06 2008-10-28 Millenium Pharmaceuticals, Inc. Proteasome inhibitors
AU2016253697A1 (en) * 2007-08-06 2016-11-24 Millennium Pharmaceuticals, Inc. Proteasome inhibitors
EA028622B1 (en) 2007-08-06 2017-12-29 Милленниум Фармасьютикалз, Инк. Proteasome inhibitors
EA034601B1 (en) * 2007-08-06 2020-02-25 Милленниум Фармасьютикалз, Инк. Process for producing boronic acids
WO2009026579A1 (en) * 2007-08-23 2009-02-26 Cornell Research Foundation, Inc. Proteasome inhibitors and their use in treating pathogen infection and cancer
US20100226597A1 (en) * 2007-09-12 2010-09-09 Dr. Reddy's Laboratories Limited Bortezomib and process for producing same
US7838673B2 (en) 2007-10-16 2010-11-23 Millennium Pharmaceuticals, Inc. Proteasome inhibitors
SI2318419T1 (en) * 2008-06-17 2015-07-31 Millennium Pharmaceuticals, Inc. Boronate ester compounds and pharmaceutical compositions thereof
AU2013204874B2 (en) * 2008-09-29 2016-11-10 Millennium Pharmaceuticals, Inc. Derivatives of 1-amino-2-cyclobutylethylboronic acid
AR075090A1 (en) 2008-09-29 2011-03-09 Millennium Pharm Inc ACID DERIVATIVES 1-AMINO-2-CYCLLOBUTILETILBORONICO PROTEOSOMA INHIBITORS, USEFUL AS ANTI-BANKER AGENTS, AND PHARMACEUTICAL COMPOSITIONS THAT UNDERSTAND THEM.
EP2238973A1 (en) 2009-04-07 2010-10-13 Cephalon France Lyophilized preparations of proteasome inhibitors
CN101899062B (en) * 2009-05-26 2015-04-15 上海威智医药科技有限公司 Synthesis technology of alpha-chiral boric acid and boric acid ester
EP2280016A1 (en) 2009-07-27 2011-02-02 LEK Pharmaceuticals d.d. New synthetic route for the preparation of alpha-amino boronic esters via substituted alk-1-ynes
EP2270019A1 (en) 2009-06-19 2011-01-05 LEK Pharmaceuticals d.d. New synthetic route for the preparation of alpha-amino boronic esters
JP2012530115A (en) * 2009-06-19 2012-11-29 レツク・フアーマシユーテイカルズ・デー・デー Novel synthetic route for the preparation of α-aminoboronic acid derivatives via substituted alk-1-ynes
WO2011087822A1 (en) 2009-12-22 2011-07-21 Cephalon, Inc. Proteasome inhibitors and processes for their preparation, purification and use
US20110178287A1 (en) 2010-01-19 2011-07-21 Cerulean Pharma Inc. Cyclodextrin-based polymers for therapeutic delivery
US20130085277A1 (en) 2010-02-09 2013-04-04 Ranbaxy Laboratories Limited Process for the preparation of bortezomib
CN101781326B (en) * 2010-02-11 2013-08-21 福建南方制药股份有限公司 Intermediate for preparing chiral aminoboronic acid and preparation method thereof
WO2011107912A1 (en) 2010-03-04 2011-09-09 Ranbaxy Laboratories Limited Polymorphic forms of bortezomib
US8263578B2 (en) 2010-03-18 2012-09-11 Innopharma, Inc. Stable bortezomib formulations
JP5661912B2 (en) * 2010-03-18 2015-01-28 イノファーマ，インコーポレイテッド Stable bortezomib formulation
RU2012146101A (en) 2010-03-31 2014-05-10 Милленниум Фармасьютикалз, Инк. 1-AMINO-2-CYCLOPROPYLETHYL BORONIC ACID DERIVATIVES
CN101812026B (en) * 2010-04-12 2013-08-28 亚邦医药股份有限公司 Method for synthesizing bortezomib
CA2799202C (en) 2010-05-18 2016-07-05 Cerulean Pharma Inc. Compositions and methods for treatment of autoimmune and other diseases
WO2012048745A1 (en) 2010-10-14 2012-04-19 Synthon Bv Process for making bortezomib and intermediates for the process
TW201309303A (en) 2011-03-03 2013-03-01 Cephalon Inc Proteasome inhibitor for the treatment of lupus
CN102206188B (en) * 2011-04-08 2013-02-27 苏州二叶制药有限公司 Preparation method for N-(pyrazine-2-yl carbonyl)-L-phenylalanine
US8497374B2 (en) 2011-05-12 2013-07-30 Scinopharm Taiwan, Ltd. Process for preparing and purifying bortezomib
CN102268029B (en) * 2011-05-19 2013-10-09 苏州二叶制药有限公司 Preparation method of compound (1S, 2S, 3R, 5S)-pinanediol-L-phenylalanine-L-leucine boric acid ester
JP5944986B2 (en) 2011-06-22 2016-07-05 セファロン、インク． Proteasome inhibitors and processes for their preparation, purification, and use
CN102351890B (en) * 2011-09-30 2014-07-02 重庆泰濠制药有限公司 Method for synthesizing bortezomib
CN102492021B (en) * 2011-12-13 2013-10-23 重庆泰濠制药有限公司 Preparation process for bortezomib
WO2013092979A1 (en) * 2011-12-22 2013-06-27 Ares Trading S.A. Alpha-amino boronic acid derivatives, selective immunoproteasome inhibitors
CN103374026A (en) * 2012-04-27 2013-10-30 重庆医药工业研究院有限责任公司 Preparation method of bortezomib midbody
CN103450331B (en) * 2012-06-05 2016-05-25 山东新时代药业有限公司 A kind of process for purification of bortezomib
KR20150067175A (en) * 2012-09-11 2015-06-17 시플라 리미티드 Process for preparing of bortezomib
WO2014072985A1 (en) 2012-11-06 2014-05-15 Natco Pharma Limited Novel boronic acid derivatives as anti cancer agents
EP2919786A4 (en) 2012-11-16 2016-06-01 Shilpa Medicare Ltd Crystalline bortezomib process
EP2928898B1 (en) 2012-12-07 2021-04-14 Venatorx Pharmaceuticals, Inc. Beta-lactamase inhibitors
CN103897027A (en) * 2012-12-29 2014-07-02 曹亚英 Key intermediate crystal form, preparation method and application of key intermediate crystal form in bortezomib synthesis
CN103897026A (en) * 2012-12-29 2014-07-02 朱继东 Crystal form of bortezomib key intermediate, and preparation method and application of crystal form
EP2943204B1 (en) 2013-01-10 2019-03-13 Venatorx Pharmaceuticals Inc Beta-lactamase inhibitors
EP2986619A1 (en) 2013-04-16 2016-02-24 Cipla Limited Process for the preparation of bortezomib mannitol ester
CN104211758B (en) * 2013-05-29 2020-06-12 深圳翰宇药业股份有限公司 Preparation method of bortezomib
CN103497233B (en) * 2013-09-30 2015-04-08 哈药集团技术中心 Preparation method for bortezomib
CN103554219A (en) * 2013-10-01 2014-02-05 昆明贵研药业有限公司 Method for preparing bortezomib
KR101691353B1 (en) * 2013-12-09 2016-12-30 주식회사 경보제약 Manufacturing method for Bortezomib and new intermediate thereof
US10167311B2 (en) 2014-02-03 2019-01-01 Ohio State Innovation Foundation Boronic acid esters and pharmaceutical formulations thereof
UA121389C2 (en) 2014-05-20 2020-05-25 Мілленніум Фармасьютікалз, Інк. Boron-containing proteasome inhibitors for use after primary cancer therapy
JP6622721B2 (en) 2014-06-11 2019-12-18 ベナトルクス ファーマシューティカルズ，インク． Beta-lactamase inhibitor
JP6420629B2 (en) * 2014-10-30 2018-11-07 ボーグワーナー インコーポレーテッド Chain guide and chain tensioner arm
DE102015204151A1 (en) * 2015-03-09 2016-09-15 Adidas Ag Ball, in particular soccer ball, and method of making a ball
JP6223508B2 (en) * 2016-06-27 2017-11-01 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． Proteasome inhibitor
EP3494121B1 (en) 2016-08-04 2021-10-06 Venatorx Pharmaceuticals, Inc. Boron-containing compounds
KR20190127681A (en) * 2017-02-17 2019-11-13 프레세니어스 카비 온콜로지 리미티드 Improved Preparation of Boric Acid Ester
SG11201908181XA (en) 2017-03-06 2019-10-30 Venatorx Pharmaceuticals Inc Solid forms and combination compositions comprising a beta-lactamase inhibitor and uses thereof
CN110959008A (en) 2017-05-26 2020-04-03 维纳拓尔斯制药公司 Penicillin binding protein inhibitors
EP3630783A4 (en) 2017-05-26 2021-03-03 Venatorx Pharmaceuticals, Inc. Penicillin-binding protein inhibitors
US11414437B2 (en) 2017-07-28 2022-08-16 Chengdu Origin Biotechnology Limited Company Borate compound, and synthesis method therefor and uses thereof
EP3676272A4 (en) 2017-09-02 2021-04-21 Sun Pharmaceutical Industries Limited Process for the preparation of ixazomib citrate
CN111187336B (en) * 2018-11-14 2022-05-20 正大天晴药业集团股份有限公司 Refining method of bortezomib
US11964993B2 (en) 2021-07-03 2024-04-23 Shilpa Pharma Lifesciences Limited Crystalline bortezomib process

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4525309A (en) * 1983-03-15 1985-06-25 Washington State University Research Foundation, Inc. Lewis acid catalysis of the homologation of boronic esters with haloalkylmetal reagents
US4537773A (en) 1983-12-05 1985-08-27 E. I. Du Pont De Nemours And Company α-Aminoboronic acid derivatives
US4499082A (en) 1983-12-05 1985-02-12 E. I. Du Pont De Nemours And Company α-Aminoboronic acid peptides
US4701545A (en) 1986-02-12 1987-10-20 Washington State University Research Foundation, Inc. Preparation of α,α-dihaloalkyl boronic esters
US5242904A (en) 1987-06-05 1993-09-07 The Dupont Merck Pharmaceutical Company Peptide boronic acid inhibitors of trypsin-like proteases
US5250720A (en) 1987-06-05 1993-10-05 The Dupont Merck Pharmaceutical Company Intermediates for preparing peptide boronic acid inhibitors of trypsin-like proteases
US5187157A (en) 1987-06-05 1993-02-16 Du Pont Merck Pharmaceutical Company Peptide boronic acid inhibitors of trypsin-like proteases
EP0315574A3 (en) 1987-11-05 1990-08-22 Hoechst Aktiengesellschaft Renin inhibitors
US5106948A (en) 1988-05-27 1992-04-21 Mao Foundation For Medical Education And Research Cytotoxic boronic acid peptide analogs
US6083903A (en) 1994-10-28 2000-07-04 Leukosite, Inc. Boronic ester and acid compounds, synthesis and uses
WO2002059131A1 (en) 2001-01-25 2002-08-01 Millennium Pharmaceuticals, Inc. Formulation of boronic acid compounds
WO2003033507A1 (en) 2001-10-12 2003-04-24 Kyorin Pharmaceutical Co., Ltd. Benzylmalonic acid derivatives and proteasome inhibitors contaiing the same
WO2003033506A1 (en) * 2001-10-12 2003-04-24 Kyorin Pharmaceutical Co., Ltd. Aminoborane acid derivative and proteasome inhibitory drug containing the same
FI4008721T3 (en) 2004-03-30 2024-03-19 Millennium Pharm Inc Synthesis of boronic ester and acid compounds
WO2009004350A1 (en) * 2007-07-03 2009-01-08 Pliva Hrvatska D.O.O. Methods for preparing bortezomib and intermediates used in its manufacture
US7838673B2 (en) * 2007-10-16 2010-11-23 Millennium Pharmaceuticals, Inc. Proteasome inhibitors
JP2012530115A (en) * 2009-06-19 2012-11-29 レツク・フアーマシユーテイカルズ・デー・デー Novel synthetic route for the preparation of α-aminoboronic acid derivatives via substituted alk-1-ynes

Also Published As

Publication number Publication date
NL1033190A1 (en) 2007-04-23
UY28830A1 (en) 2005-09-30
UY35578A (en) 2016-01-08
BRPI0509587A (en) 2007-09-25
CN108329337B (en) 2021-06-25
EP1756121A2 (en) 2007-02-28
EP3385267B1 (en) 2021-09-29
RS65253B1 (en) 2024-03-29
CN111925385B (en) 2023-11-21
CN1960996A (en) 2007-05-09
MX367324B (en) 2019-08-15
US20160362449A1 (en) 2016-12-15
IL219856A0 (en) 2012-06-28
NO343966B1 (en) 2019-07-29
JP5894952B2 (en) 2016-03-30
CN108329337A (en) 2018-07-27
DK1756121T3 (en) 2012-01-09
CN103396427B (en) 2018-04-13
NL1028639A1 (en) 2005-10-20
JP6193960B2 (en) 2017-09-06
UA90108C2 (en) 2010-04-12
KR20070007873A (en) 2007-01-16
JP5414625B2 (en) 2014-02-12
TWI386212B (en) 2013-02-21
US20180265546A1 (en) 2018-09-20
US7714159B2 (en) 2010-05-11
NO338905B1 (en) 2016-10-31
US20190330270A1 (en) 2019-10-31
CA2738706C (en) 2014-10-14
PE20142402A1 (en) 2015-02-04
SI1756121T1 (en) 2012-03-30
WO2005097809A3 (en) 2006-02-16
US10000529B2 (en) 2018-06-19
EA200601795A1 (en) 2007-04-27
NL1028639C2 (en) 2007-01-17
RS51983B (en) 2012-02-29
US20130005968A1 (en) 2013-01-03
NL1033189C2 (en) 2008-08-14
EP4008721A1 (en) 2022-06-08
HK1164320A1 (en) 2012-10-19
CL2010000350A1 (en) 2011-01-28
US20180044377A1 (en) 2018-02-15
ECSP066960A (en) 2006-12-20
EP2377868A1 (en) 2011-10-19
US20050240047A1 (en) 2005-10-27
CR8653A (en) 2007-10-23
WO2005097809A2 (en) 2005-10-20
EP2377869A1 (en) 2011-10-19
PE20060162A1 (en) 2006-04-07
LT3385267T (en) 2021-11-10
DK3385267T3 (en) 2021-11-01
CN111925385A (en) 2020-11-13
HK1100004A1 (en) 2007-08-31
RS62738B1 (en) 2022-01-31
JP2013100378A (en) 2013-05-23
AU2005230930A1 (en) 2005-10-20
EA012927B1 (en) 2010-02-26
US20210171574A1 (en) 2021-06-10
PE20110075A1 (en) 2011-02-17
NO344610B1 (en) 2020-02-10
ME01975B (en) 2015-05-20
PT2377869E (en) 2014-04-15
JP2010241816A (en) 2010-10-28
SG182998A1 (en) 2012-08-30
HK1246300A1 (en) 2018-09-07
CN107474062A (en) 2017-12-15
AR097309A2 (en) 2016-03-02
PL2377869T3 (en) 2014-07-31
US20190112334A1 (en) 2019-04-18
AU2005230930B2 (en) 2011-09-29
CA2859119A1 (en) 2005-10-20
US9862745B2 (en) 2018-01-09
CA2560886C (en) 2014-08-12
SG182999A1 (en) 2012-08-30
NL1033189A1 (en) 2007-10-22
ES2457593T3 (en) 2014-04-28
SI3385267T1 (en) 2022-04-29
JP2016056180A (en) 2016-04-21
IL178250A0 (en) 2006-12-31
EP4008721B1 (en) 2024-01-03
NO20161350A1 (en) 2006-12-22
HUE056859T2 (en) 2022-03-28
AR049374A1 (en) 2006-07-26
NO20191065A1 (en) 2006-12-22
PL1756121T3 (en) 2012-02-29
CY1115336T1 (en) 2017-01-04
CN1960996B (en) 2016-04-20
LT4008721T (en) 2024-03-25
EP1756121B1 (en) 2011-08-24
FI4008721T3 (en) 2024-03-19
HRP20110846T1 (en) 2011-12-31
ZA200608689B (en) 2007-09-26
HRP20240307T3 (en) 2024-05-10
US20220204558A1 (en) 2022-06-30
HK1257298A1 (en) 2019-10-18
CY1124753T1 (en) 2022-07-22
TW200616646A (en) 2006-06-01
DK2377869T3 (en) 2014-04-14
DOP2011000293A (en) 2011-12-15
US20200369722A1 (en) 2020-11-26
PT4008721T (en) 2024-03-21
IL219856A (en) 2015-05-31
CA2853272A1 (en) 2005-10-20
CN103396427A (en) 2013-11-20
CA2560886A1 (en) 2005-10-20
NZ550522A (en) 2010-08-27
NZ598172A (en) 2013-08-30
EP2377869B1 (en) 2014-01-29
EP3385267A1 (en) 2018-10-10
US20150038706A1 (en) 2015-02-05
IL178250A (en) 2012-06-28
US20100174072A1 (en) 2010-07-08
HRP20140339T1 (en) 2014-05-09
PL3385267T3 (en) 2022-02-14
SG10201800972PA (en) 2018-03-28
US8283467B2 (en) 2012-10-09
DK4008721T3 (en) 2024-03-25
CY1112053T1 (en) 2015-11-04
PT1756121E (en) 2011-11-30
NZ586824A (en) 2012-03-30
NL1033190C2 (en) 2007-11-27
NO20171939A1 (en) 2006-12-22
AR097310A2 (en) 2016-03-02
US20200157143A1 (en) 2020-05-21
IL219853A (en) 2015-05-31
CL2014002252A1 (en) 2014-12-05
RS53259B (en) 2014-08-29
CA2738706A1 (en) 2005-10-20
ATE521612T1 (en) 2011-09-15
NO20064893L (en) 2006-12-22
UY34969A (en) 2015-02-27
SG151322A1 (en) 2009-04-30
KR100939598B1 (en) 2010-02-01
IL219853A0 (en) 2012-06-28
JP2007530687A (en) 2007-11-01
US20210395301A1 (en) 2021-12-23
SG10201600029PA (en) 2016-02-26
PT3385267T (en) 2021-11-23
ES2899606T3 (en) 2022-03-14
ES2371652T3 (en) 2012-01-05
MY145427A (en) 2012-02-15
JP4558039B2 (en) 2010-10-06
SI2377869T1 (en) 2014-05-30

Similar Documents

Publication Publication Date Title
HRP20212002T1 (en) Synthesis of boronic ester and acid compounds
US9802886B2 (en) Process for making lysine-glutamic acid dipeptide derivatives
CN101827819B (en) Quaternary opioid carboxamides
DE60133584T2 (en) 4-ARYLPIPERIDINES AS OPIOID RECEPTOR BINDING AGENTS
Novoa et al. Sugar-based peptidomimetics as potential inhibitors of the vascular endothelium growth factor binding to neuropilin-1
ATE495442T1 (en) COMPOSITIONS AND METHODS FOR DETECTING SIROLIMUS
CN103459567A (en) Composition comprising zwitterionic geminal liquids as wettability modifiers in improved oil recovery processes
HRP20140368T1 (en) Method for preparing activated esters
IL293460A (en) Glp2 receptor agonists and methods of use
DE102016009766A1 (en) Production of bitter substance derivatives
AU2017203156B2 (en) 6-Acetylmorphine analogs, and methods for their synthesis and use
CN103145705A (en) Beta-carboline alkaloid derivatives and their preparation method and medical use
DE69821220D1 (en) RECOVERY OF POLYPHOSPHAZENE POLYACIDS OR ACID SALTS THEREOF
WO2004088312A3 (en) Fluorescently tagged ligands
AU2013316838A1 (en) Process for preparing of Bortezomib
CN104031088B (en) A kind of synthetic method of alpha-aminoalkyl phosphine compound
CN103408753A (en) Thermo-sensitive type collagen polypeptide polymer and preparation method thereof
Le et al. Synthesis of dendrimeric N-glyoxylamide peptide mimics
WO2002004423A1 (en) Thrombin inhibitors comprising an aminoisoquinoline group
CA3128862A1 (en) Method for producing peptide compound
CN103396347B (en) Method for synthesizing p-hydroxyl thiobenzamide
Nelissen et al. Synthesis of the orthogonally protected amino alcohol Phaol and analogs
SE544998C2 (en) Peptide conjugates of melphalan for the treatment of cancer
CN105254710A (en) Liquid phase synthesis method of antithrombotic compound BNW
TH122128A (en) Method for producing acelic acid derivatives